Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Personalised Medicine 2015

Personalised Medicine 2015 Agenda

Print Agenda

Tuesday, 12 May 2015



Session Chair: Charles Cox, Head Genetics Experiment Design and Delivery, GSK Pharmaceuticals


Shaping Personalized Medicine through Partnerships
Cecilia Schott, Head Personalized Healthcare, Corporate Business Development Global Product & Portfolio Strategy, AstraZeneca, United States of America

The deeper understanding of the molecular mechanisms of diseases creates an intrinsic need for diagnostic tools that can predict a patient response to a drug treatment. As a result the reality of drug development is no longer a well known and established process followed by biopharmaceutical companies. The increasing speed of technology innovation associated with biomarker discovery is shaping drug development and creating new business models. When a diagnostic is co-developed with a drug to guide its therapy, the aim is that the drug and diagnostic will be incorporated in clinical practice at the same time. Biopharmaceutical companies need simultaneous access to a variety of selection tools that are not part of their core capabilities and can only be made available through partnerships. Bringing together two industries, biopharmaceutical and diagnostics, which have very different business strategies, requires flexibility and creativity to deliver better patient outcomes.


Carlos CaldasKeynote Presentation

Personalised Breast Cancer Medicine
Carlos Caldas, Group Leader, Cancer Research UK, Cambridge Institute, United Kingdom


Coffee and Networking


Blood-based Biomarker Assays for Personalised Tumour Therapy
Thomas Krahn, Head of Global Biomarker Research Department, Bayer Pharma Ag, Germany

Blood based biomarker for early diagnosis and patient stratification, detection of circulating tumour DNA in cancer patients and Isolation and molecular analysis of circulating tumour cells will be discussed in the presentation.


Clinical Implications of Intratumoral Heterogeneity in High Grade Serious Ovarian Cancer
James Brenton, Senior Group Leader, Cancer Research UK, United Kingdom


Lunch and Networking

Session Chair: Iain Miller, European Personalized Medicine Association


Nitzan RosenfeldKeynote Presentation

Monitoring the Cancer Genome in Plasma using Circulating DNA
Nitzan Rosenfeld, Senior Group Leader, Cancer Research UK and CSO, Inivata Ltd., United Kingdom

Cell-free DNA in plasma contains circulating tumour DNA (ctDNA). This can be used as a non-invasive ‘liquid biopsy’ to assess cancer mutations, to monitor tumour burden, and to study tumour evolution.


Strategy of Sequencing the Whole Genome in Clinical Practice with Illumina X Ten
Jurgen Eils, Head, German Cancer Research Centre, Germany

Resources and infra-structure required for playing the leading role in clinical sequencing will be highlighted in this presentation. Furthermore the aspects of precision oncology and the relating IT challenges will be discussed.


Coffee and Networking


Pathway Illumination for Disease Research - Psychiatric Disorders and Antidepressant Treatment Response
Christoph Turck, Head, Max Planck Institute of Psychiatry, Germany

Biomarkers predicting a priori whether an individual patient will respond to the treatment of choice and an early distinction of responders and non-responders during antidepressant therapy can have a significant impact for realizing strategic treatment.


End of Day One

Wednesday, 13 May 2015

Session Chair: Liz Harrington, Director of Translation Science, Astrazeneca


“Big Data” – A Key to Personalized Medicine?
Andreas Schuppert, Vice President, Bayer Technology Services GmbH, Germany

In this presentation we demonstrate on a heterogeneous set of gene expression data from cancer studies, that integration of Big Data and mechanistic understanding of disease propagation provides a systematic approach for significant improvement of the reliability of model predictions.


Mark CaulfieldKeynote Presentation

Genomics England: The 100,000 Genomes Project
Mark Caulfield, Chief Scientist, Queen Mary University of London, United Kingdom

The 100,000 Genomes Project focusses on whole genome sequencing of rare inherited diseases, cancers and infections and will create a life-course resource for research and health.


Coffee and Networking


Integrated Genetics – The Advent of the $100 Genome to Support Clinical Studies
Charles Cox, Head Genetics Experiment Design and Delivery, GSK Pharmaceuticals, United Kingdom


Personalized Medicine Patents – Opportunities and Challenges
Claudia Meinken, European Patent Attorney, Patents and Trademarks for Life Sciences, Germany

The presentation will provide an overview on patentable subject matter in connection with personalized medicine highlighting the challenges arising when it comes to the enforcement of personalized medicine patents.


Lunch and Networking

Session Chair: Claudia Meinken, European Patent Attorney, Patents and Trademarks for Life Sciences


The Emerging Commercial Paradigm for Personalized Medicine: Recent Developments and EU Market Access
Iain Miller, Co-Founder, Healthcare Strategies Group, United Kingdom

In this presentation, Dr. Miller will discuss market access in the EU and UK, with a particular emphasis on technology review by NICE in the UK. He will also discuss some important recent developments in the field of PM, including immunotherapy stratification, regulatory and reimbursement trends.


Supporting Innovation in Companion Diagnostics: The Regulator’s View
Rosalind Polley, Senior Medical Device Specialist, Medicines & Healthcare Products Regulatory Agency (MHRA), United Kingdom

Background on current and future regulation of in vitro diagnostic devices in Europe as this relates to companion diagnostics used to determine treatment.


Coffee and Networking


Global Market Access for Companion Diagnostics
Kristin Ciriello Pothier, Partner & Managing Director/Life Sciences Leader, Ernst and Young LLP, United States of America
Scott Palmer, Vice President , Ernst & Young LLP, United States of America

This presentation will highlight the evolving landscape of companion diagnostics, with a focus on innovative marketing and partnering strategies.


Close of Conference

Add to Calendar ▼2015-05-12 00:00:002015-05-13 00:00:00Europe/LondonPersonalised Medicine 2015Personalised Medicine 2015 in